The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.
about
Shanghai eye treatment outbreak: bevacizumab therapy for AMD in ChinaAnti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical applicationBevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialIs monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration?Pharmacotherapies for diabetic retinopathy: present and future.Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.Current and emerging therapies for the treatment of age-related macular degenerationInhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factorIntravitreal bevacizumab in retinopathy of prematurity: an interventional case series.Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results.Immediate effect of intravitreal injection of bevacizumab on intraocular pressure.Idiopathic choroidal neovascular membrane in a young femaleTherapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularizationLocal injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study.The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life.Retinopathy of prematurity promising newer modalities of treatment.The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.[Age-related macular degeneration and risk of stroke].Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.Current treatments in diabetic macular oedema: systematic review and meta-analysisArterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.Corneal neovascularization: an anti-VEGF therapy review.Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and Meta-analysis.Regression of iris neovascularization after subconjunctival injection of bevacizumab.Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degenerationCombined therapy for diabetic macular edemaPharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model.Preoperative visual acuity among cataract surgery patients and countries' state of development: a global study.Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.Lasting controversy on ranibizumab and bevacizumab.Vascular endothelial growth factor biology: clinical implications for ocular treatmentsInsight into 144 patients with ocular vascular events during VEGF antagonist injectionsDelayed corneal epithelial healing after intravitreal bevacizumab: a clinical and experimental study.Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales' disease.Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 casesA Systematic Review.
P2860
Q27008066-49FF7056-9C65-44EB-BC0F-25D3FED051D7Q28082140-2717449D-AFD9-4453-894E-D9744C090071Q28294611-D383D081-2077-41B6-B35F-6685AC41077BQ30436143-626F3AFD-AB97-4145-839A-CAAAF811D35BQ33294882-13619AB3-F37C-4BE5-8A34-F914070C6373Q33401326-BF277D93-CBED-49EA-863A-660F5DF01494Q33492370-C91E8D81-9AA3-43D5-B2BB-A842F5443FB7Q33505319-43CDCF42-C166-4736-843F-03EC1632FBD7Q33819829-54336622-1624-4CAC-B352-9EC1AD9138C6Q33873875-1C3D4A1B-0A83-466E-99EC-C81CA52D4B4DQ33959122-90FFD8A7-069C-4ED0-8E20-0B0F041371A9Q33968693-FD614F44-6074-4E50-9C98-5DBA18E32793Q33993740-4C359AC9-77D5-4E49-A3D3-DBCB35FC4FD0Q34012249-F6AED6B0-CB95-4BD5-909D-76653360F3FEQ34078081-40F5465B-A3AB-4074-919E-05141E49E4A0Q34115840-79C2FF60-E6F3-4A3B-8B95-5D6BC87DAF61Q34160687-09A5ACB6-ED71-4923-88A7-24007C26717AQ34192101-28BBBF43-F307-48CD-8F5C-1BB0C75BE1EDQ34378757-0A5CB207-DA17-4CBE-95C0-0C4F1764FC52Q34389315-51A98F0A-5F39-45B1-AC6C-888DD77BED15Q34493789-CE631810-AFBA-4B68-A26E-4C7E4D4226DAQ34606190-E75A3A18-22FC-4BA7-BF83-AFCF51B9DC50Q34627103-4C0EF8E0-ABB2-412C-AF9D-85CA3DAA4372Q34641522-3C76BB5D-6153-407E-B7DC-77CB4212C1D3Q34735711-B4B2CF17-9FD8-44F8-826F-8CF0BB5B0864Q34889150-A6BCD005-8F7A-4FAF-9984-F7215ECAF0FFQ35016867-82D905BD-0EB7-4CF6-834E-A1BEA7407F1BQ35060360-4DA28494-2B3D-42F4-A203-F7F4235684FDQ35067115-03B19EAD-DE50-4C92-A81F-92510FFD8D11Q35220993-A281644B-E870-4D73-B983-C18DFDDA4393Q35533147-87F9CEC4-3D72-48E4-9B57-A60158F187A5Q35585178-3EC29C7C-B57B-4BB9-8C5A-EBDDB7C18881Q35641933-5617771A-DC2F-4CAC-AE4E-10DD83D5DE18Q35762769-0E347FA7-B72D-4A22-BB9F-EEA320A2EB62Q35822200-E5025C16-D5A2-43A5-9F79-66B69E5E1353Q35835470-BDBA41FF-B4DF-45F0-A530-1E70EC168C6BQ35935978-97449BA0-9AA6-4120-93D2-20E514784D0EQ35956190-179D45AD-977D-4A21-BCE6-58F1A683962EQ36172391-15ACB514-7FB5-47B7-BB56-945F95693A2BQ36245370-386435EA-3C79-409C-B04C-719AF5F951A6
P2860
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The International Intravitreal ...... assess drug safety worldwide.
@ast
The International Intravitreal ...... assess drug safety worldwide.
@en
type
label
The International Intravitreal ...... assess drug safety worldwide.
@ast
The International Intravitreal ...... assess drug safety worldwide.
@en
prefLabel
The International Intravitreal ...... assess drug safety worldwide.
@ast
The International Intravitreal ...... assess drug safety worldwide.
@en
P2093
P2860
P356
P1476
The International Intravitreal ...... assess drug safety worldwide.
@en
P2093
P J Rosenfeld
P2860
P304
P356
10.1136/BJO.2006.099598
P407
P577
2006-07-19T00:00:00Z